| Document |
Document Title |
|
WO/2012/027482A2 |
Disclosed are compounds, compositions and methods related PPAR antagonists. Certain compounds are effective at inhibiting PPARs. The compositions can be used to inhibit PPARs, treat cancer and treat metabolic disorders.
|
|
WO/2012/021963A1 |
Therapeutic sulfonamide compounds with the formula R-Q-Ar-SO2NH2 are disclosed, wherein R is an aryl, hetaryl, alkyl or cycloalkyl group, Q is the group -L(CH2)n-, wherein n = 0,1 or 2 and L is the group - NHCXNH-, -NHC(S)SNH-, -NHCONHCS...
|
|
WO/2012/021486A2 |
The present disclosure relates to acylsulfonamides and processes for their preparation. The processes involve a target-guided synthesis approach, whereby a thioacid and a sulfonyl azide are reacted in the presence of a biological target ...
|
|
WO/2012/020130A1 |
The present invention relates to phenalkylamine derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such phenalkylamine derivatives, and the use of s...
|
|
WO/2012/020133A1 |
The present invention relates to tetraline and indane derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such tetraline and indane derivatives, and ...
|
|
WO/2012/020513A1 |
This method for producing a fluorine-containing sulfonylimide compound ((Rf1SO2)(Rf2SO2)N•M) comprises: a first step of obtaining a reaction solution by reacting a perfluoroalkyl sulfonyl fluoride (Rf1SO2F) and ammonia; a second step o...
|
|
WO/2012/018635A2 |
The present invention provides acylsulfonamides including bumetanide derivatives and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these compounds and methods for their u...
|
|
WO/2012/017166A2 |
or an addition salt thereof with pharmaceutically acceptable acids, for use thereof in a method for treatment of a pathological condition linked to an excessive effect of TNF-alpha and for use thereof in a method for treatment of the hum...
|
|
WO/2012/013727A1 |
The invention relates to cyclopropylamine compounds, in particular the compounds of Formula (I), and their use in therapy, including e.g. in the treatment or prevention of cancer, a neurological disease or condition, or viral infection.
|
|
WO/2012/014127A1 |
The present invention relates to sulfonamides derivatives as 5-lipoxygenase (5-LO) inhibitors and a process for their synthesis. The present invention also relates to pharmacological compositions containing these sulfonamides derivatives...
|
|
WO/2012/010752A1 |
The invention relates to a process for preparing salts of formulae (RfSO3)n Xn+ (I) or [(RfSO2)(RSO2)N]nXn+ (II) in which: - Rf represents any radical comprising one or more fluorine atoms, - n is an integer varying from 1 to 6, - X is a...
|
|
WO/2012/008435A1 |
Disclosed is a novel biaryl amide derivative represented by formula (1) and having an affinity for the aldosterone receptor; also disclosed is a pharmaceutically acceptable salt thereof. (In the formula, A is any of the groups represente...
|
|
WO/2012/007868A2 |
The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new...
|
|
WO/2012/007883A1 |
The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new...
|
|
WO/2011/161201A1 |
A compound of formula (I). The compound is useful for treating cancer and inflammatory diseases. A pharmaceutical composition containing the compound.
|
|
WO/2011/158321A1 |
Disclosed is an ionic compound which can be used to obtain a cured product having excellent antibacterial and oxygen permeation properties. Further disclosed are a composition which contains the ionic compound, and an ocular lens, a hydr...
|
|
WO/2011/148971A1 |
A process for the preparation of fluorine-containing sulfonyl imide compounds, which includes subjecting a mixture of a fluorine-containing sulfonyl imide compound represented by (Rf1SO2)(Rf2SO2)NH (1) and a sulfonic acid compound repres...
|
|
WO/2011/148958A1 |
A process for the preparation of fluorine-containing imide compounds represented by (Rf1SO2)(Rf2SO2)NH, characterized by reacting a fluorine-containing sulfonic acid represented by Rf1SO3H with a fluorine-containing sulfonamide represent...
|
|
WO/2011/148961A1 |
Disclosed is a method for producing a fluorine-containing imide compound, which uses inexpensive starting materials and is highly safe and highly productive. The fluorine-containing imide compound ((Rf1SO2)(Rf2SO2)NH) is produced by reac...
|
|
WO/2011/149213A2 |
The present invention relates to a novel derivative having inhibitory activity against 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), a preparation method thereof, and a pharmaceutical composition containing the same as an active ...
|
|
WO/2011/144054A1 |
Provided are dibenzocyclooctene lignan derivatives having the following structural formula and their uses in the treatment of viral hepatitis. Said dibenzocyclooctene lignan derivatives have bioactivity of anti-hepatitis B virus (anti-HB...
|
|
WO/2011/145669A1 |
Disclosed are the compound represented by formula (I) which is useful as a therapeutic or prophylactic agent for various partial and/or generalized epileptic seizures, or a salt thereof. [In the formula, ring A and ring B independently r...
|
|
WO/2011/144992A1 |
A polymer electrolyte includes a fluorine-containing structure having an alicyclic 1,3-disulfonimide in a principal chain or side chain of the polymer. A battery includes the polymer electrolyte. An imide monomer is able to introduce a f...
|
|
WO/2011/120926A1 |
A description is given of 4-cyclopropyl-2-[(5-oxo-4,5-dihydro-1,2,4-triazol-1‑yl)(th
io)carbonylaminosulfonyl]benzoic acid derivatives of the general formula (I) and salts thereof, in which the respective substituents have the defini...
|
|
WO/2011/119560A1 |
The present invention relates to a mixture of polyfluoroalkylsulfonamido alkyl amines including at least one polyfluoroalkylsulfonamido alkyl amine and its analog, a di(polyfluoroalkylsulfonamido alkyl) amine. The invention also relates ...
|
|
WO/2011/119551A1 |
The present invention relates to a polyfluoroalkylsulfonamido alkyl halide intermediate. The invention also relates to the use of the aforementioned halide intermediate to prepare a mixture of polyfluoroalkylsulfonamido alkyl amines incl...
|
|
WO/2011/119555A1 |
The present invention relates to aminosulfonate and aminocarboxylate compositions derived from a mixture of polyfluoroalkylsulfonamido alkyl amines including at least one polyfluoroalkylsulfonamido alkyl amine and its analog, a di(polyfl...
|
|
WO/2011/119345A2 |
Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti apoptotic Bcl-2 protein.
|
|
WO/2011/108690A1 |
The disclosed composition containing a compound represented by general formula (I) (refer to the Description for the definitions of the symbols used in the formula), or a salt thereof, has excellent CaSR agonist effects and provides phar...
|
|
WO/2011/107705A1 |
The present invention relates to ketobenzofuran derivatives of the general formula (D) shown below, as well as to a method for synthesising same by coupling a quinonimine and an enaminone by a Nenitzescu reaction and to the intermediates...
|
|
WO/2011/108724A1 |
An object is to provide a CaSR agonist agent that has excellent CaSR agonist effects, and particularly, a pharmaceutical product that can prevent or remedy diabetes or obesity by the effect of CaSR activation. The aforementioned object i...
|
|
WO/2011/104127A1 |
The invention pertains to a compound generating an acid of the formula (I) or (II), for instance corresponding sulfonium and iodonium salts, as well as corresponding sulfonyloximes, Formula (I) and Formula (II), wherein X is CH2 or CO; Y...
|
|
WO/2011/098610A1 |
A carbonic anhydrase IX (CA IX) inhibitor which comprises a compound of general formula: R-NH-CX-NH-(CH2)n-Ar-Q-SO2-NH2 or a pharmaceutically-acceptable salt, derivative or prodrug thereof; wherein n = 0, 1 or 2; Q is O or NH; X is O or ...
|
|
WO/2011/088561A1 |
The present disclosure provides novel compounds as well as uses, methods, and compositions of treating, or reducing the risk of, HIV-infection.
|
|
WO/2011/087717A1 |
Fluorinated arylene-containing compounds and fluorinated polymers formed from fluorinated arylene-containing compounds, and methods are described. Fluorinated polymers formed from fluorinated arylene-containing compound can be used to pr...
|
|
WO/2011/083275A1 |
The invention relates to pyridine-pyridinone derivatives of general formula (I), where R1, R2, R3, R4, n, n', V, W, Y, Z and Ar are as defined in the description, as well as to methods for preparing the same and to the therapeutic uses t...
|
|
WO/2011/079439A1 |
The present invention relates to a kind of novel carbene ligands and corresponding new ruthenium catalysts, which are highly active and selective for ROMP and RCM reactions. It discloses the significant electronic effect of different sub...
|
|
WO/2011/078101A1 |
Provided is an adamantanamine derivative useful as an important intermediate for a 11βHSD-1 inhibitor. The adamantanamine derivative is represented by general formula (II) [wherein R10 is a group represented by the general formula: -(CR...
|
|
WO/2011/071951A2 |
The invention provides certain N-acyloxysulfonamide and N-hydroxy-N-acylsulfonamide derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions....
|
|
WO/2011/071947A2 |
The invention provides certain bis-acylated hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the invent...
|
|
WO/2011/067266A1 |
Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing...
|
|
WO/2011/067174A1 |
Provided herein are compounds of the formula (I), as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing...
|
|
WO/2011/065502A1 |
Disclosed are: a method for producing a fluorosulfonyl imide salt, which is capable of reducing the impurity content and can be continuously performed for a long time; and a fluorosulfonyl imide salt. The fluorosulfonyl imide salt has a ...
|
|
WO/2011/061590A1 |
The present invention relates to carboxamide derivatives of Formula (I), where B1, B2, X, L, n, R, R1, R2, Z1, Z2, Rx and Ry are as defined in the claims, as compounds and compositions for inhibiting Human Immunodeficiency Virus (HIV) an...
|
|
WO/2011/058154A1 |
Provided herein are compounds of the formula (I) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing ...
|
|
WO/2011/055142A2 |
The invention provides 1,4-quinones, 1,4-naphthoquinones and their sulphur analogues as inhibitors of hNAT1, an enzyme which is both a diagnostic marker and drug target for breast cancer. Some of the compounds of the invention are also c...
|
|
WO/2005/060456A9 |
The present invention relates to methods of treating ADAMTS-S-associated diseases and particularly osteoarthritis comprising administering an agent capable an of modulating ADMATS-5 activity to a subject afflicted with the disease. The a...
|
|
WO/2011/052601A1 |
Provided are a novel ionic organic compound represented by general formula (I), which is effective as a carbon nanotube dispersant, and a method for producing said compound by means of simple processes. (In the formula, R1, R2, and R3 re...
|
|
WO/2011/048004A1 |
This invention relates to compounds of formula I, their use as inhibitors of the microsomal prostaglandin E2 synthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevent...
|
|
WO/2011/047795A1 |
The present invention relates to substituted benzosulphonamide compounds of general formula (I) : in which R1, R2, R3, R4, R5 and A are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and ...
|
